Core Insights - The enthusiasm of private equity institutions for researching A-share listed companies has significantly increased in October, with a notable rise in the number of participating institutions, covered stocks, and overall research frequency compared to September [1] Group 1: Research Participation - In October, 1,072 private equity institutions participated in research, covering 549 listed companies across 29 Shenwan primary industries, with a total of 5,242 research instances, representing an 87.95% month-on-month increase from September's 2,789 instances [1] - Among the participating institutions, 49 billion-level private equity institutions also saw a significant increase in research activity, with their research instances rising by over 70% [1] Group 2: Market Drivers - The increase in research activity is driven by two main factors: the market's phase adjustment at the end of September, which provided a favorable allocation window due to valuation declines, and the concentrated disclosure period of Q3 reports, making company performance a focal point for private equity institutions [1] Group 3: Industry Focus - The electronic, pharmaceutical, and electric equipment sectors emerged as the top three areas of interest for private equity institutions, each receiving over 700 research instances [1] - The electronic industry has maintained its position as the most researched sector for several months, driven by the acceleration of domestic substitution in the semiconductor industry and the initiation of the consumer electronics innovation cycle [2] - The pharmaceutical industry is favored for its diverse individual stocks and broad subfields, allowing for a diversified investment approach by private equity institutions [2] - The electric equipment sector benefits from the continuous growth in new energy installations, with stable performance from upstream and downstream enterprises, attracting intensive research to verify production capacity and order status [2] Group 4: Active Institutions - Among the participating private equity institutions, 137 conducted at least 10 research instances in October, with Shenzhen Shangcheng Yipin Asset Management Co., Ltd. and Guangdong Zhengyuan Private Fund Management Co., Ltd. being the most active, each exceeding 100 research instances in a single month [2]

Group 1 - In August, a total of 1,152 private equity firms participated in research on A-share listed companies, covering 27 industries and 641 stocks, with a total of 6,053 research instances, representing a significant month-on-month increase of 243.34% [1] - The increase in private equity research activity in August is attributed to three main factors: the intensive disclosure period of semi-annual reports, the upward trend in the A-share market enhancing institutional confidence, and the emergence of structural opportunities in certain sectors [1] - Notable stock performances include Dayuan Pump Industry (603757) in the machinery sector, which saw a cumulative price increase of 108.80%, and Oulutong (300870) in the power equipment sector, which increased by 101.91% despite only being researched twice [1] Group 2 - The top ten stocks with the highest cumulative price increases in August were predominantly from technology-related sectors such as telecommunications, electronics, and power equipment, indicating strong interest from private equity firms in high-growth sectors [2] - The medical and biological sector was the most researched, with Mindray Medical (300760) receiving 117 research instances, making it the most focused stock by private equity firms in August [2] - The electronic sector also had significant representation, with three stocks—Crystal Optoelectronics (002273), Feikai Materials (300398), and Anji Technology—each receiving over 50 research instances [2] Group 3 - Smaller private equity firms, particularly those managing under 500 million yuan, emerged as the main contributors to research activity, with Shenzhen Shangcheng Yipin Asset Management leading with 143 research instances [3] - Other smaller firms such as Shanghai Tianyi Investment Management and Xuanbu Investment also ranked among the top ten in research frequency [3] - Shanghai Gao Yi Asset Management, the only large-scale firm in the top ten, conducted 67 research instances, showing a particular preference for the medical and biological sector with 17 related stocks researched [3]